Analysts See $-0.24 EPS for Protagonist Therapeutics, Inc. (PTGX) as of May, 9

April 17, 2018 - By Patrick Harkless

Earnings report for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is anticipated On May, 9., Faxor reports. Analysts have expectation on stock’s earnings per share of $-0.24. That’s up 71.43 % from last year’s $-0.84 earnings per share. Wall Street now sees 60.00 % negative EPS growth despite Protagonist Therapeutics, Inc. last quarter’s EPS of $-0.15. PTGX reached $8.93 on during the last trading session after $0.01 change.Protagonist Therapeutics, Inc. has volume of 163,872 shares. Since April 17, 2017 PTGX has declined 34.14% and is downtrending. PTGX underperformed the S&P500 by 45.69%.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide chemical entities to address various unmet medical needs.The firm is valued at $188.46 million. It primarily focuses on developing oral peptide drugs.Currently it has negative earnings. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease ; and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.